Search Results

You are looking at 71 - 80 of 735 items for :

  • All content x
Clear All
Open access

V Guarnotta, C Di Stefano, A Santoro, A Ciresi, A Coppola, and C Giordano

conventional GCs in patients with AI, on anthropometric parameters, glucose and lipid metabolism, and cardiovascular risk estimated by the FRS for non-diabetic patients ( 11 ) and the United Kingdom Prospective Diabetes Study (UKPDS) risk engine for diabetic

Open access

Eric Seidel, Gudrun Walenda, Clemens Messerschmidt, Benedikt Obermayer, Mirko Peitzsch, Paal Wallace, Rohini Bahethi, Taekyeong Yoo, Murim Choi, Petra Schrade, Sebastian Bachmann, Gerhard Liebisch, Graeme Eisenhofer, Dieter Beule, and Ute I Scholl

, H and K); 1.25 µm (C, F, I and L). Pathways involving steroid metabolism and transport, apoptosis, cell growth and Wnt signaling are altered in mitotane-resistant cell lines We compared gene expression profiles of six mitotane

Open access

K L Gatford, G K Heinemann, S D Thompson, J V Zhang, S Buckberry, J A Owens, G A Dekker, C T Roberts, and on behalf of the SCOPE Consortium

Introduction The insulin-like growth factors (IGFs), IGF1 and IGF2, are important regulators of placental and foetal development, as well as postnatal growth and metabolism. In humans, circulating IGF1 peaks in adolescence and then falls with age

Open access

Estíbaliz Castillero, Ana Isabel Martín, Maria Paz Nieto-Bona, Carmen Fernández-Galaz, María López-Menduiña, María Ángeles Villanúa, and Asunción López-Calderón

addition to inflammatory mediators, dysregulation of metabolism is an important contributor to inflammatory cachexia (2) . Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that modulate metabolism and inflammation

Open access

Anru Wang, Xueqin Yan, Cai Zhang, Caiqi Du, Wenjun Long, Di Zhan, and Xiaoping Luo

body composition or lipid and glucose metabolism (e.g., the use of thyroid medication, thiazolidinediones or metformin) were excluded. All anthropometric and biochemical measures were recorded at baseline and after 6 months of the intervention

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

with worsening of glucose metabolism. This is an established feature of pasireotide treatment in preclinical and clinical studies of acromegaly ( 44 , 45 ). We noted that both cases developed marked elevations in HbA1c and this required multi

Open access

Xiangyu Gao, Wanwan Sun, Yi Wang, Yawen Zhang, Rumei Li, Jinya Huang, and Yehong Yang

of diabetic patients in a certain region might lead to bias. Furthermore, few studies have addressed the correlation between clinical biochemical features such as lipid metabolism, liver and kidney function, and islet autoimmunity in patients with T2

Open access

Johan Verhelst, Anders F Mattsson, Cecilia Camacho-Hübner, Anton Luger, and Roger Abs

waist decreased significantly at Y1 (80.3 vs 77.4%; P  < 0.001), whereas impaired glucose metabolism increased (17.1 vs 23.3%; P  < 0.001) as well as unfavourable HDL (48.2 vs 50.9%; P  = 0.011). No change was observed for blood pressure and

Open access

Line K Johnson, Kirsten B Holven, Njord Nordstrand, Jan R Mellembakken, Tom Tanbo, and Jøran Hjelmesæth

, total (g) 17.0 85.0  in fruit/vegetables (g) 17.0 13.0  in LMR (g) 72.0  (E %) 6.2 32 Added sugar (g) 1.3 77  (E%) 0.5 29 Fibre (g) 34.4 45.5 Outcomes The main outcomes were the 8-week changes in blood lipids, glucose metabolism, BP and uric acid

Open access

Zeeshan Javed, Maria Papageorgiou, Leigh A Madden, Alan S Rigby, Eric S Kilpatrick, Stephen L Atkin, and Thozhukat Sathyapalan

.clinicaltrials.gov (NCT03008551) and conducted in the Academic Diabetes, Endocrinology and Metabolism Research Centre at Hull Royal Infirmary. All participants gave their informed consent in writing. Inclusion/exclusion criteria and study procedures have been explained